Viridian loses $18M in Q2, continues to advance drug through trials
BOULDER — Viridian Therapeutics’ (NASDAQ: VRDN) $18 million net loss for the second quarter of 2021 was nearly triple year-over-year the $6.4 million the biopharmaceutical company lost in the second quarter of 2020, according to an earnings report filed Wednesday.
Research and development expenses were up more than 200% in the second quarter, from $3.8 million in 2020 to $12.6 million this year. General and administrative expenses were also up, increasing 140% from $2.7 million to $6.5 million. In both cases, the company attributed the increased spending to advancement of Viridian’s drugs through testing programs.
Viridian is on track to submit to…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!